Are brigatinib and brigatinib the same drug?

Brigatinib and brigatinib are actually the same drug, they both refer toBrigatinib, an innovative treatment for a specific type of non-small cell lung cancer (NSCLC). The drug belongs to a class of kinase inhibitors designed to treat non-small cell lung cancer that has spread to other parts of the body.

The core mechanism of brigatinib, or brigatinib, is its ability to precisely block the action of abnormal proteins. These abnormal proteins originally signal cancer cells to reproduce, prompting them to grow and spread uncontrollably. By inhibiting this signaling process, brigatinib can effectively slow down or even prevent the further spread of cancer cells, thereby providing patients with longer survival and higher quality of life.

This drug has shown significant clinical results in the treatment of non-small cell lung cancer, especially in cases where traditional treatments have been difficult to respond. Its emergence has brought new life to many patients who had lost hope of treatment. Of course, like all drugs, brigatinib may be associated with some side effects during use, so it needs to be used under the guidance of a professional doctor.

In general, brigatinib and brigatinib are the same drug, they are bothdifferent names of brigatinib. With its unique mechanism of action and significant therapeutic effect, this drug occupies an important position in the treatment of non-small cell lung cancer. As medical research continues to deepen, we expect it to bring good news to more patients.

Brigatinib is currently on the market in China and has been included in domestic medical insurance reimbursement items. The domestically marketed brigatinib is 90mg*28 tablets, for example, and the price after reimbursement by medical insurance is around 6,000 yuan. It is understood that there are a variety of related generic versions of brigatinib on the market overseas. These generic versions are from Laos and Bangladesh. Taking 90mg*30 tablets as an example, the price ranges from 900 to 3,200 yuan. If the patient needs an overseas version, please consult a regular overseas medical consulting company to find out.